GFA
MRNA icon

Godfrey Financial Associates’s Moderna MRNA Stock Holding History

Godfrey Financial Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82K Hold
26
– – ﹤0.01% 696
2026
Q1 		$1.32K Hold
26
– – ﹤0.01% 727
2025
Q4 		$767 Buy
+26
New +$706 ﹤0.01% 795

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Godfrey Financial Associates's MRNA Position: Q2 2026 in Review

Godfrey Financial Associates held its Moderna (MRNA) position steady in Q2 2026 at 26 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Godfrey Financial Associates first reported a position in MRNA in Q4 2025 and has held it in 3 quarters since. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Godfrey Financial Associates held 26 shares of Moderna worth $1.82K as of Q2 2026.
  • Godfrey Financial Associates left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Godfrey Financial Associates's portfolio in Q2 2026, its #696 holding.
  • Godfrey Financial Associates first reported a position in Moderna in Q4 2025 and has held it in 3 quarters since.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Godfrey Financial Associates's 13F filing for Q2 2026, filed 11 Aug 2026.